In exploratory analyses , adjusted mean Unified Parkinson 's Disease Rating Scale ( UPDRS ) PartsII + III scores ( excluding ex-placebo recipients ) remained substantially improved from DB baseline scores prior to pramipexole introduction , at -@ and -@ points amongst ex-DB-ER and ex-DB-IR recipients after @ weeks of pramipexole ( @ DB plus @ OL ) in early PD , and -@ and -@ after up to @ weeks ( up to @ DB plus @ OL ) in advanced PD .